Synta Pharma offers positive ganetespib interim results, +15% premarket

Synta Pharmaceuticals (SNTA+15% premarket after announcing "positive" Interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer at a breast cancer symposium.

Early results demonstrated the drug is clinically active as a single-agent in both HER2+ and triple-negative metastatic breast cancers, SNTA says.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs